For the quarter ended September 2025, Clorox (CLX Quick QuoteCLX - Free Report) reported revenue of $1.43 billion, down 18.9% over the same period last year. EPS came in at $0.85, compared to $1.86 in the year-ago quarter.

The reported revenue represents a surprise of +3.23% over the Zacks Consensus Estimate of $1.38 billion. With the consensus EPS estimate being $0.78, the EPS surprise was +8.97%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Clorox performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Organic Revenue Growth - Health and Wellness: -19% compared to the -25.2% average estimate based on four analysts.
• Organic Revenue Growth - International: -2% compared to the -2.4% average estimate based on four analysts.
• Organic Revenue Growth - Lifestyle: -23% versus the four-analyst average estimate of -17.3%.
• Organic Revenue Growth - Household: -19% versus the four-analyst average estimate of -20.5%.
• Organic Sales Growth (non-GAAP): -17% compared to the -19.7% average estimate based on four analysts.
• Net Revenue- Health and Wellness: $565 million versus the four-analyst average estimate of $520.56 million. The reported number represents a year-over-year change of -19.1%.
• Net Revenue- International: $253 million compared to the $240.84 million average estimate based on four analysts. The reported number represents a change of -2.3% year over year.
• Net Revenue- Lifestyle: $245 million versus the four-analyst average estimate of $264 million. The reported number represents a year-over-year change of -23.4%.
• Net Revenue- Household: $362 million versus the four-analyst average estimate of $354.35 million. The reported number represents a year-over-year change of -19%.
• Income before income taxes- Health and Wellness: $124 million versus $153.37 million estimated by two analysts on average.
• Income before income taxes- Corporate and Other: $-48 million compared to the $-100.3 million average estimate based on two analysts.
• Income before income taxes- International: $19 million versus $28.5 million estimated by two analysts on average.

View all Key Company Metrics for Clorox here>>>

Shares of Clorox have returned -8.7% over the past month versus the Zacks S&P 500 composite's +2.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.